Belite Bio Inc banner

Intrinsic Value

Not Available for BLTE

There is not enough data to reliably calculate the intrinsic value for Belite Bio Inc.

Do our valuations actually work? See backtest results .

Alternatives to BLTE

Fundamental Analysis

What Belite Bio Does

Pharmaceuticals Health Care

Belite Bio is a clinical-stage drug developer focused on eye diseases that damage the retina and can lead to vision loss. Its main work is developing oral medicines for conditions such as Stargardt disease and dry age-related macular degeneration, where patients need long-term treatment to slow or prevent further damage.

Headquarters
United States of America US
Employees
41
IPO date
Apr 29, 2022
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
Belite Bio Inc

Wall St Price Targets

Capital Returns

Buyback Yield
LOCKED
Debt Paydown Yield
LOCKED

Competitive Landscape

Ownership

BLTE Insider Trading
Buy and sell transactions by insiders